Guardant Health AMEA

Calling all oncologists! Join us on November 6th from 7.30pm to 9.00pm (IST) for a webinar discussion entitled “MRD Roundtable: Enhancing patient outcomes through minimal residual disease detection and surveillance monitoring”. Register for this webinar today at https://lnkd.in/gSzzaYy7 This webinar will feature leading medical oncologists from all over India. The chairperson of the session will be Dr. Shekhar Patil from HCG Cancer Centre in Bangalore and the speaker for this session is Dr. Viraj Lavingia from Shalby Hospital in Ahmedabad. This webinar will be moderated by Dr. Amit Rauthan from Manipal Hospital in Bangalore. The panellists of this webinar session include Dr. Sai Vivek Velkuru from Aster Hospital in Bangalore, Dr. Aparna Dhar from Max Super Speciality Hospital in New Delhi, Dr. Palanki Satya Dattatreya from Renova Soumya Cancer Centre in Hyderabad, Dr. Rejiv Rajendranath from Apollo Hospital in Chennai and Dr. Rajat Bajaj from Fortis Hospital in Noida. We look forward to your participation in this webinar. Speak to your doctor today about minimal residual disease (MRD) testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC to find out more about our MRD test which can help oncologists identify patients at a higher risk of recurrence. This test is for prescription use only. #guardanthealth #guardanthealthamea #webinar #MRD #minimalresidualdisease #surveillancemonitoring #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

Happy Diwali! - from all of us at Guardant Health. Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #diwali #happydiwali #happydeepavali #celebration #india #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #CGP #cancerpatients #medicaloncologists

Our CEO, Simranjit Singh, will be sharing his views at the 5th Health Insurance Innovation Congress (HIIC) Asia Pacific 2024 as a speaker on the Leaders Panel for Revolutionizing Health and Wellness which will touch on Leveraging Innovative Ecosystems for Enhanced Services. This event is taking place on 21st and 22nd October 2024 at the Dusit Thani Laguna Singapore in the Laguna Ballroom on Level 3. https://lnkd.in/grrmDt7X Join us at HIIC APAC 2024, where the future of healthcare and insurance takes centre stage. Reserve your seat: https://lnkd.in/gESSXU_Y   Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #HIIC #HIICAPAC #healthinsurance #healthcare #healthinnovation #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #CGP #cancerpatients #medicaloncologists

Recently, Nature Medicine published findings from the SCRUM-Japan GOZILA study. The study, spearheaded by a distinguished research group at the National Cancer Center Hospital East in Kashiwa, Japan, delved into the effects of personalized treatment based on the Guardant360 CDx test results in 4,037 patients with advanced cancer. Study findings showed that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer. https://lnkd.in/g5bU-Bmg The results revealed that 24% of participants were able to receive targeted treatment tailored to them based on comprehensive genomic profiling results from the Guardant360 CDx test. The patients who received targeted treatment guided by comprehensive liquid biopsy results lived approximately twice as long as those who did not. Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #guardanthealthjapan #pressrelease #news #GOZILAStudy #NatureMedicine #publication #guardant360 #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #medicaloncologists

In this series of advancing patient access to next-generation sequencing (NGS) for cancer, we will be highlighting some of the key findings in a whitepaper recently published by Asia Pacific Medical Technology Association (APACMed) titled “Advancing Patient Access to NGS for Cancer in APAC: Key considerations and a value assessment framework”. In territories with limited NGS access for cancer testing, it is observed that the mortality-to-incidence ratios (MIR) are higher, compared to territories with greater NGS access.¹'² https://lnkd.in/dbq-RMxj Despite existing efforts in APAC to address cancer through National Cancer Control Plans (NCCPs), clinical outcomes for cancer in APAC still lag behind the West, with estimated mortality-to-incidence ratio (MIR) of APAC (0.5) being much higher as compared to Western and Northern EU, and USA (0.32).¹'² Many territories within APAC have not included NGS in their NCCPs, contributing to the lack of NGS access, which may potentially impede these territories’ progress in improving cancer outcomes.² This whitepaper presents an overview of the status of access to NGS-based cancer care in APAC and actions required to improve access, including a first-of-its-kind value assessment framework for NGS tailored to the regional context. Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. Reference: 1. Cancer today. Accessed September 20, 2024. https://lnkd.in/d-sF4XCF 2. Advancing Patient Access to NGS for Cancer in APAC: Key considerations and a value assessment framework. Accessed September 20, 2024. https://lnkd.in/gXitBHrQ #guardanthealth #guardanthealthamea #liquidbiopsy #liquidissolid #APACMed #whitepaper #newpublication #patientaccess #nextgenerationsequencing #NGS #NGSreimbursement #comprehensivegenomicprofiling #CGP #medicaloncologists

One day to go! Calling all oncologists! Join us on October 9th from 7.00pm to 8.15pm (GMT+8) for a webinar discussion entitled “MRD Roundtable: Enhancing patient outcomes through minimal residual disease detection and surveillance monitoring”. Register for this webinar today at https://lnkd.in/gYrZs6QU This webinar will feature Dr. Chih-Chien Wu, a Consultant Surgeon from the division of colorectal surgery in Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan and Dr. Valeriya Semenisty, Director of the Oncology Department in Hillel Yaffe Medical Center in Hadera, Israel. The session will be moderated by Dr. Suyog Jain M.D. from Guardant Health AMEA. We look forward to your participation in this webinar. Speak to your doctor today about minimal residual disease (MRD) testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC to find out more about our MRD test which can help oncologists identify patients at a higher risk of recurrence. This test is for prescription use only. #guardanthealth #guardanthealthamea #webinar #MRD #minimalresidualdisease #surveillancemonitoring #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

Check out this publication featured in the Frontiers in Oncology titled “Utilization of tissue-free minimal residual disease testing in colorectal cancer (CRC) patients from Asia and Middle East” led by several leading medical oncologists in Asia and the Middle East.¹ https://lnkd.in/gUCaRygA Detection of circulating tumor DNA (ctDNA) post curative therapy indicating minimal residual disease is linked to higher chances of recurrence in CRC.² This retrospective analysis of real-world data describes how physicians in Asia and the Middle East currently apply a commercially available tissue-free minimal residual disease (MRD) assay, Guardant Reveal™, in their routine practice.¹ This real-world study, which included 215 patients, reported that in stage II CRC, a higher proportion of MRD tests were ordered within 12 weeks of surgery (presumably to support the decision to proceed with adjuvant chemotherapy). While in stage III CRC, a higher proportion of the MRD tests were ordered after 12 weeks of surgery (presumably to support the decision to modify adjuvant chemotherapy).¹ Congratulations to all co-authors of this study which includes Dr. Shaheenah Dawood, Dr. Marwan Akasheh, Dr. Viraj Lavingia as well as our Chief Medical Officer, Dr. Steve Olsen and Dr. Suyog Jain M.D., Dr. Nisarg Joshi M.D., Sandra Hsing and Hsiao-Yu Jen from Guardant Health AMEA’s team. (Guardant Reveal results are provided as ctDNA positive or ctDNA negative without any suggestions or recommendations for therapy. Physicians make these treatment decisions independently.) Speak to your doctor today about minimal residual disease (MRD) testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC to find out more about our MRD test which can help oncologists identify patients at a higher risk of recurrence. This test is for prescription use only. References: 1. Jain, Suyog & Dawood, Shaheenah & Lavingia, Viraj & Aderka, Dan & Tahover, Esther & Hsieh, Yao-Yu & Temper, Mark & Goldman, Alesya & Akasheh, Marwan & Olsen, Steve & Hsing, Sandra & Joshi, Nisarg & Jen, Hsiao-Yu. (2024). Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East. Frontiers in Oncology. 14. 10.3389/fonc.2024.1426941 2. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127-134. doi:10.1038/s41591-022-02115-4 #guardanthealth #guardanthealthamea #MRD #minimalresidualdisease #colorectalcancer #CRC #medicalpublication #newpublication #medicalresearch #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #CGP #cancerpatients #medicaloncologists

October is Breast Cancer Awareness Month. Breast cancer is the most frequently diagnosed and the second most common mortality-causing cancer among women worldwide.¹ Predictive molecular biomarkers may optimize the selection of effective therapies in patients with metastatic breast cancer.² The current and emerging National Comprehensive Cancer Network (NCCN) guideline-recommended somatic biomarkers for patients with metastatic breast cancer include ERBB2 (HER2) amplification and activating mutations in HER2, ESR1, PIK3CA, pathogenic mutations of BRCA1 and BRCA2, fusions in NTRK1/2/3 and RET genes, as well as microsatellite instability (MSI-High).³ The Guardant360® liquid biopsy test can test for all these biomarkers simultaneously. ESR1 mutations, for example, are present in up to 40% of ER+/HER2- advanced breast cancers.⁴ Liquid biopsies using cell-free DNA testing exhibit high sensitivity and specificity in detecting ESR1 mutations in patients with breast cancer.⁴ The U.S. FDA has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ and this FDA approval was the first time these patients had an approved treatment for their specific type of cancer and a blood-based companion diagnostic.⁵ Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. Reference: 1.      Abbasi HQ, Maryyum A, Khan AM, Shahnoor S, Oduoye MO, Wechuli PN. Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence. Int J Surg. 2023;109(7):2157-2158. Published 2023 Jul 1. doi:10.1097/JS9.0000000000000334 2.      Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. Int J Mol Sci. 2017;18(1):85. Published 2017 Jan 4. doi:10.3390/ijms18010085 3.      NCCN Guidelines on Invasive Breast Cancer Version 4. 2024.  https://lnkd.in/gMazvgA. Accessed on September 25, 2024 4.      Raei M, Heydari K, Tabarestani M, et al. Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy. BMC Cancer. 2024;24(1):908. Published 2024 Jul 28. doi:10.1186/s12885-024-12674-z 5.      Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer. News release. Guardant Health, Inc. January 30, 2023. Accessed September 24, 2024. https://shorturl.at/jG2gH #breastcancer

In newly diagnosed advanced nonsquamous non–small cell lung cancer (NSCLC), undergenotyping and incomplete genotyping for genomic biomarkers that are guideline-recommended poses a significant challenge to informative and timely clinical decision-making.¹ In one of the largest prospective, multicentre cell-free DNA (cfDNA) studies in previously untreated metastatic non-small cell lung cancer (mNSCLC), it was demonstrated that a validated, highly sensitive and highly specific, clinically utilized comprehensive cell-free DNA (cfDNA) test (Guardant360®) detects guideline-recommended biomarker-positive patients at a rate similar to standard of care (SOC) tissue genomic testing, with high concordance and significantly faster return of test results (in 9 days vs. 15 days) leading to complete genotyping of the guideline-recommended biomarkers in more patients (95% vs. 31%).¹ These findings from the NILE (Non-invasive versus Invasive Lung Evaluation) study demonstrate that Guardant360 can be a clinically viable alternative to tissue-based genotyping for first-line therapy selection in patients with newly diagnosed advanced NSCLC.¹ This is one of many factors that makes our liquid biopsy solid. Visit us at https://lnkd.in/dVEkKyRC to find out more about our comprehensive genomic profiling tests that can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. Reference: 1. Leighl NB, Page RD, Raymond VM, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019;25(15):4691-4700. doi:10.1158/1078-0432.CCR-19-0624 #guardanthealth #guardanthealthamea #liquidbiopsy #liquidissolid #lungcancer #NSCLC #comprehensivegenomicprofiling #nextgenerationsequencing #NGS #cancerpatients #medicaloncologists

Our Chief Executive Officer, Simranjit Singh, participated in a panel discussion entitled “Shifting From Reactive to Proactive Health Care” at the Milken Institute 2024 Asia Summit on September 19th together with an esteemed panel of experts from FWD Group Insurance, Singapore’s National University Health System, Roche Diagnostics and Novo Holdings Equity Asia. In his presentation, Simran shared that there is currently a critical shift in healthcare from reactive to proactive approaches and that this transition is particularly important in the fight against colorectal cancer, Singapore’s most prevalent cancer, accounting for 17% of all cancer cases, around 4,000 new diagnoses annually, causing nearly 1,000 deaths each year.¹ Watch the recording here: https://lnkd.in/g6ZkA5wX Despite these statistics, Singapore has low adherence rates (26.7%) for traditional colorectal cancer screening methods such as colonoscopies and stool tests.² Yet, early detection of CRC is key. Patients diagnosed at an early stage have a 91% five-year survival rate, compared to just 14% for metastatic disease.³ This is where innovation can be a game changer. The recent FDA approval of Guardant Health’s Shield test, a blood-based screening tool, presents a less invasive and more accessible option. By simplifying the screening process, we hope to see increased adherence and earlier detection, ultimately saving lives and aligning with the broader move towards proactive healthcare. Visit us at https://lnkd.in/eukRmVRW to find out more about the Shield blood test. This test is for prescription use only. Speak to your doctor today about colorectal cancer screening with a simple blood draw. References: 1. Global Cancer Observatory: Cancer Today: International Agency for Research on Cancer. https://lnkd.in/gMrJGSbZ. Accessed September 20, 2024. 2. Wong RK, Wong ML, Chan YH, Feng Z, Wai CT, Yeoh KG. Gender differences in predictors of colorectal cancer screening uptake: a national cross sectional study based on the health belief model. BMC Public Health. 2013;13:677. Published 2013 Jul 23. doi:10.1186/1471-2458-13-677 3. Marcellinaro R, Spoletini D, Grieco M, et al. Colorectal Cancer: Current Updates and Future Perspectives. J Clin Med. 2023;13(1):40. Published 2023 Dec 21. doi:10.3390/jcm13010040 #guardanthealthamea #guardanthealth #MIGLOBAL #milkeninstitute #asiasummit #proactivehealthcare #liquidissolid #colorectalcancer #healthiersg #FasterCures #MinistryofHealthSingapore #comprehensivegenomicprofiling #precisiononcology #medicaloncologists #liquidbiopsy